Insulet Corporation $PODD Shares Sold by Munich Reinsurance Co Stock Corp in Munich

Munich Reinsurance Co Stock Corp in Munich lessened its position in shares of Insulet Corporation (NASDAQ:PODD) by 68.6% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,045 shares of the medical instruments supplier’s stock after selling 11,039 shares during the quarter. Munich Reinsurance Co Stock Corp in Munich’s holdings in Insulet were worth $768,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Larson Financial Group LLC raised its position in shares of Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Insulet during the 4th quarter valued at about $26,000. Elyxium Wealth LLC purchased a new position in shares of Insulet in the 4th quarter valued at about $28,000. DV Equities LLC purchased a new position in shares of Insulet in the 4th quarter valued at about $28,000. Finally, Mcguire Capital Advisors Inc. acquired a new position in Insulet in the 4th quarter worth about $29,000.

Insulet Stock Down 2.1%

PODD stock opened at $147.48 on Friday. The firm has a market cap of $10.23 billion, a PE ratio of 27.57, a PEG ratio of 1.19 and a beta of 1.08. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. The firm’s 50 day moving average price is $154.45 and its 200-day moving average price is $177.72. Insulet Corporation has a one year low of $126.40 and a one year high of $354.88.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, topping the consensus estimate of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The company had revenue of $801.70 million during the quarter, compared to analyst estimates of $787.39 million. During the same period in the prior year, the business posted $1.17 earnings per share. The firm’s revenue for the quarter was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, equities research analysts anticipate that Insulet Corporation will post 6.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on PODD. The Goldman Sachs Group restated a “buy” rating and issued a $205.00 target price on shares of Insulet in a research report on Wednesday, May 27th. Citigroup increased their price objective on Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Raymond James Financial restated an “outperform” rating and issued a $180.00 price objective on shares of Insulet in a report on Thursday, August 6th. Bank of America lowered their target price on shares of Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Finally, TD Cowen dropped their target price on shares of Insulet from $294.00 to $144.00 and set a “hold” rating for the company in a report on Thursday, August 6th. Fourteen investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Insulet currently has a consensus rating of “Hold” and an average target price of $195.40.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.